Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
By How Much Is The Omics-Based Clinical Trials Market Expected To Expand Between 2025 And 2029?
The omics-based clinical trials market has experienced significant expansion in recent years. This market is set to grow from $29.10 billion in 2024 to $31.71 billion in 2025, with a compound annual growth rate (CAGR) of 8.9%. Historically, this growth can be attributed to a rising number of clinical trials incorporating omics technologies, an increased emphasis on translational research, growing government support and funding, the expanding availability of biobanks and biospecimens, and heightened awareness regarding the advantages of precision therapies.
The omics-based clinical trials market is set to experience significant expansion over the coming years. It is projected to reach $44.08 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.6%. This growth during the forecast period is driven by factors such as the increasing demand for personalized medicine, greater adoption of multi-omics methodologies, the rising incidence of chronic and rare diseases, increased investment in genomic research and biotechnology, and a growing emphasis on biomarker discovery. Prominent trends for the forecast duration encompass advancements in next-generation sequencing (NGS) technologies, the integration of artificial intelligence with omics platforms, technological progress in bioinformatics tools, improvements in proteomics and metabolomics platforms, and the integration of multi-omics data.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp
Which Drivers Are Impacting The Omics-Based Clinical Trials Market?
The anticipated expansion of the omics-based clinical trials market is driven by the growing need for personalized medicine. This medical strategy customizes disease prevention, diagnosis, and treatment plans based on each patient’s unique characteristics. The increasing adoption of personalized medicine is fueled by progress in genomic technologies, which enable quicker and more economical analysis of individual genetic profiles to direct specific treatments. Omics-based clinical trials facilitate personalized medicine through the identification of distinct genetic, proteomic, and metabolic profiles, leading to more precise and efficacious treatment strategies customized for individual patients. As an illustration, the Personalized Medicine Coalition, a US-based professional membership organization, reported in February 2023 that 12 new personalized medicines were approved in 2022. This figure constituted approximately 34% of all newly approved therapies, signifying a notable rise compared to prior years. Consequently, the rising requirement for personalized medicine is a key impetus behind the expansion of the omics-based clinical trials market.
What Are The Major Segments Identified In The Omics-Based Clinical Trials Market?
The omics-based clinical trials market covered in this report is segmented
1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders
5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories
Subsegments:
1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing
2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping
3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis
4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling
Which Competitive Trends Are Defining The Omics-Based Clinical Trials Market Structure?
Leading companies within the omics-based clinical trials market are concentrating on innovative solutions, such as HiFi sequencing technology, to enhance the accuracy, speed, and depth of multi-omics data analysis, ultimately improving trial outcomes and personalized treatment strategies. HiFi sequencing is defined as a next-generation sequencing (NGS) technology that generates long, highly accurate reads through circular consensus sequencing (CCS), enabling comprehensive and precise analysis of genomes, transcriptomes, and epigenomes. For instance, in October 2024, Pacific Biosciences of California Inc., a US-based biotechnology company, in collaboration with the Agency for Science, Technology, and Research (A*STAR), a Singapore-based research and product development agency, and Macrogen Inc., a South Korea-based biotechnology company, launched a state-of-the-art lab to accelerate genomics innovation in Singapore with cutting-edge long-read sequencing technology. This facility empowers researchers to conduct advanced genomic studies with greater precision and speed, supporting a wide range of applications, including whole genome sequencing, transcriptomics, epigenetics, and metagenomics. The lab also fosters collaboration among global scientists and local institutions, aiming to accelerate discoveries in personalized medicine, rare disease diagnostics, and precision oncology. Additionally, it offers training programs and shared access to high-throughput sequencing infrastructure, promoting capacity-building and innovation within the Asia-Pacific region.
Which Key Players Are Driving Competition In The Omics-Based Clinical Trials Market?
Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, and BioAro Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report
Which Region Currently Holds The Largest Share Of The Omics-Based Clinical Trials Market?
North America was the largest region in the omics-based clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Omics-Based Clinical Trials Market Report:
https://www.thebusinessresearchcompany.com/customise?id=27369&type=smp
Browse Through More Reports Similar to the Global Omics-Based Clinical Trials Market 2025, By The Business Research Company
Bitumen Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/bitumen-global-market-report
Asphalt Additives Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report
Asphalt Pavers Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/asphalt-pavers-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
